Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (151-160 of 264) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylateGloria N Mattiuzzi, Jorge E Cortes, Moshe Talpaz, et al.
Cancer|December 24, 2003
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phaseThomas B Sneed, Hagop M Kantarjian, Moshe Talpaz, et al.
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controlsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood|October 24, 2002
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Leukemia|May 17, 2019
The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myelomaMarc S Raab, Sheeba K Thomas, Enrique M Ocio, et al.
Blood|June 17, 2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
Blood|February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyJorge E Cortes, Moshe Talpaz, Francis Giles, et al.
Pageof 27

Showing results (151-160 of 264) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylateGloria N Mattiuzzi, Jorge E Cortes, Moshe Talpaz, et al.
Cancer|December 24, 2003
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phaseThomas B Sneed, Hagop M Kantarjian, Moshe Talpaz, et al.
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controlsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood|October 24, 2002
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Leukemia|May 17, 2019
The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myelomaMarc S Raab, Sheeba K Thomas, Enrique M Ocio, et al.
Blood|June 17, 2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
Blood|February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyJorge E Cortes, Moshe Talpaz, Francis Giles, et al.
Pageof 27